OTC and small cell lung carcinoma: Notably, it has been demonstrated that, while knockdown of ASS1 in H69 cells (SCLC) with or without BCT-100 treatment exhibits no significant differences, blocking of OTC sensitizes H841 cells (SCLC) to BCT-100 exposure [13].